APC/Cyanine7 anti-mouse/human CD45R/B220 Antibody

Pricing & Availability
Clone
RA3-6B2 (See other available formats)
Regulatory Status
RUO
Other Names
B220
Isotype
Rat IgG2a, κ
RA3-6B2_APCCy7_060308
C57BL/6 splenocytes stained with RA3-6B2 APC/Cyanine7
  • RA3-6B2_APCCy7_060308
    C57BL/6 splenocytes stained with RA3-6B2 APC/Cyanine7
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability
103223 25 µg $88.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103224 100 µg $196.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45R, also known as B220, is an isoform of CD45. It is a member of the protein tyrosine phosphatase (PTP) family with a molecular weight of approximately 180-240 kD. CD45R is expressed on B cells (at all developmental stages from pro-B cells through mature B cells), activated B cells, and subsets of T and NK cells. CD45R (B220) is also expressed on a subset of abnormal T cells involved in the pathogenesis of systemic autoimmunity in MRL-Faslpr and MRL-Fasgld mice. It plays a critical role in TCR and BCR signaling. The primary ligands for CD45 are galectin-1, CD2, CD3, and CD4. CD45R is commonly used as a pan-B cell marker; however, CD19 may be more appropriate for B cell specificity.

Technical data sheet

Product Details

Verified Reactivity
Mouse, Human
Reported Reactivity
Cat
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Abelson murine leukemia virus-induced pre-B tumor cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone RA3-6B2 has been described to react with an epitope on the extracellular domain of the transmembrane CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues. Additional reported applications (for the relevant formats) include: immunoprecipitation1, in vitro and in vivo modulation of B cell responses2-4, immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections5,6, and spatial biology (IBEX)14,15.

Application References

(PubMed link indicates BioLegend citation)
  1. Coffman RL. 1982. Immunol. Rev. 69:5. (IP)
  2. George A, et al. 1994. J. Immunol. 152:1014. (Activ)
  3. Asensi V, et al. 1989. Immunology 68:204. (Activ)
  4. Domiati-Saad R, et al. 1993. J. Immunol. 151:5936. (Activ)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Monteith CE, et al. 1996. Can. J. Vet. Res. 60:193. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Chang C L-T, et al. 2007. J. Immunol. 178:6984.
  9. Fazilleau N, et al. 2007. Nature Immunol. 8:753.
  10. Lang GL, et al. 2008. Blood 111:2158. PubMed
  11. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  12. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  13. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  14. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  15. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  2. Wu Y, et al. 2023. Adv Mater. 35:e2210787. PubMed
  3. Xu H, et al. 2023. Elife. 12:. PubMed
  4. Inaba A, et al. 2023. Nat Commun. 14:2071. PubMed
  5. Griffin GK, et al. 2023. Nature. 618:834. PubMed
  6. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  7. Lawson H, et al. 2021. Stem Cell Reports. 16:2784. PubMed
  8. Rivas MA, et al. 2021. Nat Immunol. 22:240. PubMed
  9. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  10. Van Deren DA, et al. 2022. Development. 149: . PubMed
  11. Omer-Javed A, et al. 2022. Cell. 185:2248. PubMed
  12. Tessaro FHG, et al. 2022. Cell Rep. 39:110977. PubMed
  13. Gupta S, et al. 2022. Sci Adv. 8:eabn4886. PubMed
  14. Xu Y, et al. 2023. EMBO Rep. 24:e55503. PubMed
  15. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  16. Urata S, et al. 2023. Microbiol Immunol. 67:105. PubMed
  17. Yang L, et al. 2023. Acta Pharmacol Sin. :. PubMed
  18. Kang J, et al. 2023. JCI Insight. 8: . PubMed
  19. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  20. Huang Y, et al. 2015. Proc Natl Acad Sci U S A. 112:39. PubMed
  21. Chung Y, et al. 2014. J Vis Exp. 89: 51660. PubMed
  22. Ishikura S, et al. 2016. J Biol Chem. 291: 15282 - 15291. PubMed
  23. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
  24. Roco JA et al. 2019. Immunity. 51(2):337-350 . PubMed
  25. Sharma GP, et al. 2021. PLoS One. 16:e0259042. PubMed
  26. Lechuga-Vieco AV, et al. 2020. Sci Adv. 6:eaba5345. PubMed
  27. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  28. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  29. Gazit R, et al. 2014. J Exp Med. 211:1315. PubMed
  30. Stewart I et al. 2018. Immunity. 49(3):477-489 . PubMed
  31. Chen S, et al. 2022. Cancer Discov. :. PubMed
  32. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  33. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  34. Sun Y et al. 2018. Cancer cell. 34(4):643-658 . PubMed
  35. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
  36. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  37. Leimkühler NB, et al. 2020. Cell Stem Cell. 28:637. PubMed
  38. Roufaiel M, et al. 2016. Nat Immunol. 10.1038/ni.3564. PubMed
  39. Jacoby E, et al. 2016. Blood. 127: 1361 - 1370. PubMed
  40. D'Auria K, et al. 2013. Infect Immun . 81:3814. PubMed
  41. Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed
  42. Shinoda K, et al. 2020. Cell Reports. 29(13):4471-4481.e6.. PubMed
  43. Fujino T, et al. 2021. Nat Commun. 12:1826. PubMed
  44. Inoue D, et al. 2021. Nat Genet. 53:707. PubMed
  45. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  46. Zong L, et al. 2021. NPJ Aging Mech Dis. 7:25. PubMed
  47. Palm A, et al. 2016. Sci Rep. 10.1038/srep20531. PubMed
  48. Fuster JJ, et al. 2020. Cell Rep. 33:108326. PubMed
  49. Mathew NR, et al. 2021. Cell Reports. 35(12):109286. PubMed
  50. Thayer T, et al. 2011. Diabetes. 60:2144. PubMed
  51. Yoshimi A, et al. 2019. Nature. 574:273. PubMed
  52. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  53. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  54. Rogawski DS, et al. 2021. Nat Commun. 12:2792. PubMed
  55. Sochalska M, et al. 2016. Oncogene. 10.1038/onc.2016.362. PubMed
  56. Dema B, et al. 2014. J Exp Med. 211:2159. PubMed
  57. Kunimoto H, et al. 2018. Cancer Cell. 33:44. PubMed
  58. Lam WY et al. 2018. Cell reports. 24(9):2479-2492 . PubMed
  59. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  60. Muppidi J, et al. 2015. J Exp Med. 212: 2213 - 2222. PubMed
  61. Dos Santos Dias L, et al. 2021. PLoS Pathog. e1009324:17. PubMed
  62. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  63. Kleppe M et al. 2018. Cancer cell. 33(1):29-43 . PubMed
  64. Forbester JL, et al. 2020. J Virol. 94:. PubMed
  65. Soto-Díaz K, et al. 2021. Front Immunol. 12:734349. PubMed
  66. Rivas MA, et al. 2021. Front Immunol. 12:688493. PubMed
  67. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  68. Benet Z, et al. 2021. Cell Reports. 34(6):108733. PubMed
  69. Yao M, et al. 2020. Cell. 180(3):502-520. PubMed
  70. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  71. Grune J, et al. 2022. Nat Cardiovasc Res. 1:649. PubMed
  72. Rodda L, et al. 2015. J Immunol. 195: 4781 - 4791. PubMed
  73. Venturutti L, et al. 2020. Cell. 182(2):297-316.e27. PubMed
  74. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  75. Sullivan JA, et al. 2020. Cell Rep. 30:1039. PubMed
  76. St Clair JB, et al. 2017. PLoS One. 12:e0170556. PubMed
  77. Roy K, et al. 2019. Immunity. 50:616. PubMed
  78. Bei T, et al. 2021. Molecules. 26:. PubMed
  79. Panea C, et al. 2021. Commun Biol. 4:913. PubMed
  80. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
  81. Zhang C, et al. 2020. Cell Rep. 32:108206. PubMed
  82. Chauveau L, et al. 2021. EMBO Rep. 22:e52447. PubMed
  83. Lim CX, et al. 2020. Cell Rep. 3793:30. PubMed
  84. Wang YH, et al. 2019. Front Immunol. 10:1909. PubMed
  85. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  86. Yang S, et al. 2022. J Exp Med. 219:. PubMed
  87. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  88. Jacoby E, et al. 2016. Nat Commun. 7:12320. PubMed
  89. He Z, et al. 2016. Exp Hematol. 44:161-165. PubMed
  90. Fournier M, Bijl C 2015. Stem Cells Dev. 24: 2413-2422. PubMed
  91. Gough D, et al. 2014. Blood. 124:2252. PubMed
  92. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  93. Huang Y, et al. 2016. J Immunol. 196: 217 - 231. PubMed
  94. Georgoudaki A, et al. 2016. Cell Rep. 15: 2000-2011. PubMed
  95. DiToro D, et al. 2020. Immunity. 650:52. PubMed
  96. Xiao G, et al. 2018. Cell. 173:470. PubMed
  97. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  98. Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed
  99. Zhang CR, et al. 2022. Blood Cancer Discov. 3:220. PubMed
  100. Rive CM, et al. 2022. Mol Ther Methods Clin Dev. 26:4. PubMed
  101. King R, et al. 2021. Sci Adv. 7:eabj5293. PubMed
  102. Wang X, et al. 2021. EMBO J. 40:e105926. PubMed
  103. Yan-Feng L, et al. 2017. Sci Rep. 7:40133. PubMed
  104. Uribe-Herranz M, et al. 2018. JCI Insight. 3. PubMed
  105. Celik H, et al. 2018. Cancer Cell. 34:741. PubMed
  106. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  107. Kobia FM, et al. 2020. PLoS Biol. 18:e3000850. PubMed
  108. Haniuda K, et al. 2020. Cell Rep. 33:108333. PubMed
  109. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  110. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  111. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  112. Kim SK, et al. 2018. Genes Dev. 32:849. PubMed
  113. Katzmarski N, et al. 2021. Nat Immunol. 22:1382. PubMed
  114. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  115. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  116. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
  117. Baptista M, et al. 2016. Nat Commun. 7:12175. PubMed
  118. Aryal B, et al. 2016. Nat Commun. 7:12313. PubMed
  119. Andresen L, et al. 2016. PLoS One. 11: 0148428. PubMed
  120. Altin J, et al. 2014. Proc Natl Acad Sci U S A. 111:2067. PubMed
  121. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
  122. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
  123. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  124. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  125. Sato-Hashimoto M, et al. 2011. J Immunol. 187:291. PubMed
  126. Whiteley AM et al. 2017. eLife. 6 pii: e26435. PubMed
  127. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  128. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  129. BJ L, et al. 2017. J Exp Med . 10.1084/jem.20161461. PubMed
RRID
AB_313006 (BioLegend Cat. No. 103223)
AB_313006 (BioLegend Cat. No. 103224)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

B cells, T cell subset, NK cell subset

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
B cells, NK cells, T cells
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID 5788 View all products for this Gene ID
UniProt
View information about CD45R on UniProt.org

Other Formats

View All CD45R/B220 Reagents Request Custom Conjugation
Description Clone Applications
Alexa Fluor® 594 anti-mouse/human CD45R/B220 RA3-6B2 IHC-F,FC,3D IHC
APC anti-mouse/human CD45R/B220 RA3-6B2 FC
Biotin anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F
FITC anti-mouse/human CD45R/B220 RA3-6B2 FC
PE anti-mouse/human CD45R/B220 RA3-6B2 FC
PE/Cyanine5 anti-mouse/human CD45R/B220 RA3-6B2 FC
Purified anti-mouse/human CD45R/B220 RA3-6B2 FC,CyTOF®,IHC-F,IHC-P,IP,Activ
PE/Cyanine7 anti-mouse/human CD45R/B220 RA3-6B2 FC
APC/Cyanine7 anti-mouse/human CD45R/B220 RA3-6B2 FC
Alexa Fluor® 488 anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F,3D IHC
Alexa Fluor® 647 anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Alexa Fluor® 700 anti-mouse/human CD45R/B220 RA3-6B2 FC
PerCP anti-mouse/human CD45R/B220 RA3-6B2 FC
PerCP/Cyanine5.5 anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 421™ anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F
Brilliant Violet 570™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 650™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 605™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 785™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 510™ anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F,SB
Purified anti-mouse/human CD45R/B220 (Maxpar® Ready) RA3-6B2 FC,CyTOF®
Brilliant Violet 711™ anti-mouse/human CD45R/B220 RA3-6B2 FC
PE/Dazzle™ 594 anti-mouse/human CD45R/B220 RA3-6B2 FC
APC/Fire™ 750 anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 750™ anti-mouse/human CD45R/B220 RA3-6B2 FC
TotalSeq™-A0103 anti-mouse/human CD45R/B220 RA3-6B2 PG
Spark Blue™ 550 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark NIR™ 685 anti-mouse/human CD45R/B220 RA3-6B2 FC
TotalSeq™-B0103 anti-mouse/human CD45R/B220 RA3-6B2 PG
Ultra-LEAF™ Purified anti-mouse/human CD45R/B220 RA3-6B2 FC,CyTOF®,IHC-F,IHC-P,IP,Activ
TotalSeq™-C0103 anti-mouse/human CD45R/B220 RA3-6B2 PG
PE/Fire™ 640 anti-mouse/human CD45R/B220 RA3-6B2 FC
APC/Fire™ 810 anti-mouse/human CD45R/B220 RA3-6B2 FC
PE/Fire™ 700 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark Violet™ 538 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark YG™ 581 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark YG™ 570 anti-mouse/human CD45R/B220 RA3-6B2 IHC-F
PE/Fire™ 810 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark Blue™ 574 anti-mouse/human CD45R/B220 Antibody RA3-6B2 FC
Spark Violet™ 423 anti-mouse/human CD45R/B220 Antibody RA3-6B2 FC
Spark Red™ 718 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark UV™ 387 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark PLUS UV395™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Go To Top Version: 3    Revision Date: 04/25/2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Login/Register
Forgot your password? Reset Password
Request an Account